The FDA-approved iron oxide nanoparticle ferumoxytol (Feraheme) can be used for the treatment of an iron deficiency, but it can also be used to increase intracellular iron of AML cells when the leukemic cells express low levels of the iron exporter SLC40A1 (solute carrier family 40 member 1/ferroportin) [239]. The gene discussed is SLC40A1; the disease is nutritional disorder.